Switch to Upadacitinib Over Tofacitinib
For a patient currently on adalimumab, upadacitinib 15 mg once daily is the preferred switch over tofacitinib 5 mg twice daily, based on superior efficacy in achieving clinical remission and better treatment persistence, with comparable overall safety profiles.
Evidence Supporting Upadacitinib
The most recent and highest-quality evidence demonstrates upadacitinib's superiority across multiple inflammatory conditions:
Ulcerative Colitis Data (Most Compelling)
In the 2024 AGA evidence synthesis 1, upadacitinib demonstrated the highest efficacy among all advanced therapies for moderate-to-severe UC. Upadacitinib achieved clinical remission rates of 33% and 26% in induction trials, with absolute benefits of 29% and 22% over placebo—margins greater than any other advanced therapy including tofacitinib. Network meta-analysis showed upadacitinib had a relative risk of 8.52 (95% CI: 2.24-32.35) for clinical remission versus placebo, compared to tofacitinib's 5.88 (95% CI: 0.84-40.95) 1.
Real-world data from 2026 further supports this: the TRIDENT-UC study 2 found upadacitinib achieved steroid-free clinical remission in 47.6% at week 16 and 75.0% at week 52, compared to tofacitinib's 27.0% and 52.4%, respectively. After propensity score adjustment, upadacitinib showed 3.14 times higher odds of achieving steroid-free clinical remission at week 52 (95% CI: 1.22-8.12) 2.
Psoriatic Arthritis Evidence
In the SELECT-PsA 1 trial 3, upadacitinib 15 mg demonstrated ACR20 response rates of 70.6% at week 12, which was noninferior to adalimumab's 65.0%. The 30 mg dose achieved 78.5% response and was superior to adalimumab. While tofacitinib is conditionally recommended for PsA 4, direct comparison data favor upadacitinib's efficacy profile.
Rheumatoid Arthritis Data
The 2025 meta-analysis 5 comparing tofacitinib versus adalimumab found tofacitinib superior in ACR20 response (RR: 1.28; 95% CI: 1.06-1.55), but the SELECT-COMPARE study 6 demonstrated that switching from adalimumab to upadacitinib resulted in CDAI remission in 32.7% of initial non-responders through 228 weeks, with sustained efficacy.
Safety Considerations
Comparable Overall Safety
Both agents have similar overall adverse event profiles 7, 8. The 2021 consensus statement 7 notes that serious infection rates in RA and PsA studies were comparable between tofacitinib, upadacitinib, and adalimumab at approved doses.
Key Safety Differences
Tofacitinib-specific concerns:
- FDA boxed warning requires prior TNF antagonist failure before JAK inhibitor use, based on cardiovascular and malignancy data from the ORAL Surveillance study 1
- Higher risk of pulmonary embolism at 10 mg twice daily dose 9
- Five-fold increase in pulmonary embolism in patients >50 years with cardiovascular risk factors 9
- Increased herpes zoster risk, particularly in Asian populations 8
Upadacitinib-specific concerns:
- More frequent herpes zoster infections, lymphopenia, and creatine phosphokinase elevation 6
- Higher rates of acne compared to tofacitinib (OR 4.30; 95% CI: 1.86-9.95) 10
- Hepatic disorders in 9.1-12.3% (though grade 3 elevations ≤2%) 3
Critical Patient Factors
Avoid tofacitinib in:
- Patients >65 years with cardiovascular risk factors (per EMA guidance, use only if no alternative) 7
- Patients at increased risk of pulmonary embolism (heart failure, malignancy, recent surgery, inherited coagulation disorders) 9
Consider dose adjustments for both agents:
- Moderate-severe renal impairment: Tofacitinib 5 mg once daily; upadacitinib requires no adjustment 7
- Moderate hepatic impairment: Both require dose reduction 7, 11
- Drug interactions with CYP3A4 inhibitors (ketoconazole) or inducers (rifampicin) require adjustments 7
Practical Implementation
Switching protocol:
- Direct switch without washout period is safe and effective 12, 13
- Monitor complete blood count, liver enzymes at baseline and 4 weeks post-switch 14
- Check lipids at 12 weeks for upadacitinib 14
- Screen for latent TB and viral hepatitis before initiation 7
Vaccination:
- Administer zoster vaccine (Shingrix) before initiating either agent 15
- Complete all live vaccines at least 4 weeks before starting therapy 9
Monitoring thresholds for discontinuation (both agents):
- Lymphocyte count <500 cells/mm³ (confirmed by repeat testing) 15, 11
- Absolute neutrophil count <500 cells/mm³ 15, 11
- Hemoglobin <8 g/dL or decrease >2 g/dL 15, 11
Bottom Line
Upadacitinib 15 mg once daily is the preferred switch based on:
- Superior efficacy in achieving and maintaining clinical remission across multiple conditions
- Better treatment persistence (lower discontinuation rates)
- Comparable overall safety to tofacitinib at approved doses
- More favorable dosing (once daily vs. twice daily)
The primary caveat is that both agents carry FDA boxed warnings for cardiovascular events, malignancy, and thrombosis in high-risk populations. However, upadacitinib's superior efficacy profile, particularly in bio-experienced patients, makes it the preferred choice when switching from adalimumab, provided patients are appropriately screened and monitored.